Ophthalmology

Working in partnership with the National Eye Institute, Emmes has supported major clinical research that has led to treatments in age-related macular degeneration and rare diseases, including Retinitis Pigmentosa, Stargardt’s, Ushers Syndrome, and X-linked Retinoschisis.

Emmes has supported advances in cell and gene therapies for inherited and rare ophthalmic disorders.

Our work on the AREDS and AREDS 2 trials is already supporting clients at the forefront of AMD science, and our collaborations have made AREDS products available to patients at risk for Advanced AMD.

We also ran the ophthalmology clinical trials that produced IDx-DR, the first FDA approved, AI-based diagnostic system for diabetic retinopathy — a disease that blinds 24,000 people each year.